FDA Approves Lynparza for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

TUESDAY, June 6, 2023 -- The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated, metastatic, castration-resistant...